Display options
Cite
Hosono Y, Goto M, Kobayashi D, et al. Diagnostic relevance of autoantibody detection against inhibitors of apoptosis proteins in colon cancer and colon adenoma. Mol Clin Oncol. 2015;3(3):595-600doi: 10.3892/mco.2015.502.
Hosono, Y., Goto, M., Kobayashi, D., Kuribayashi, K., Tanaka, M., & Watanabe, N. (2015). Diagnostic relevance of autoantibody detection against inhibitors of apoptosis proteins in colon cancer and colon adenoma. Molecular and clinical oncology, 3(3), 595-600. https://doi.org/10.3892/mco.2015.502
Hosono, Yukie, et al. "Diagnostic relevance of autoantibody detection against inhibitors of apoptosis proteins in colon cancer and colon adenoma." Molecular and clinical oncology vol. 3,3 (2015): 595-600. doi: https://doi.org/10.3892/mco.2015.502
Hosono Y, Goto M, Kobayashi D, Kuribayashi K, Tanaka M, Watanabe N. Diagnostic relevance of autoantibody detection against inhibitors of apoptosis proteins in colon cancer and colon adenoma. Mol Clin Oncol. 2015 May;3(3):595-600. doi: 10.3892/mco.2015.502. Epub 2015 Feb 06. PMID: 26137273; PMCID: PMC4471536.
Copy Download .nbib Format: NLM
Share it on

Mol Clin Oncol. 2015 May;3(3):595-600. doi: 10.3892/mco.2015.502. Epub 2015 Feb 06.

Diagnostic relevance of autoantibody detection against inhibitors of apoptosis proteins in colon cancer and colon adenoma.

Molecular and clinical oncology

Yukie Hosono, Maki Goto, Daisuke Kobayashi, Kageaki Kuribayashi, Maki Tanaka, Naoki Watanabe

Affiliations

  1. Department of Clinical Laboratory Medicine, School of Medicine, Sapporo Medical University, Sapporo, Hokkaido 060-8543, Japan.

PMID: 26137273 PMCID: PMC4471536 DOI: 10.3892/mco.2015.502

Abstract

Autoantibodies against cancer-related antigens may be detected in the sera of patients with various types of cancer, although their clinical utility has not yet been established. In this study, we aimed to demonstrate the diagnostic relevance of autoantibody detection against inhibitor of apoptosis protein (IAP) family members in colon cancer, as compared to anti-p53 antibody, carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9. We established an ELISA system using original recombinant proteins of IAP family members (survivin, livin and X-linked IAP) and measured the expression levels in the sera of 62 healthy donors, 250 patients with colon polyps (adenoma) and 176 patients with colon cancer. When the cutoff value was set as the mean value + 2 standard deviations in healthy donors, anti-survivin exhibited the highest positivity rate (24.4%) among IAP autoantibodies in cancer patients. Furthermore, the anti-survivin antibody exhibited a high positivity rate in early-stage carcinoma and adenoma. In the combination assay, reflecting the significantly high positivity rate of CEA in stage IV tumors, the positivity rate was highest when combining the detection of anti-survivin antibody and CEA in cancer patients (50.0%), indicating that this combination may not be useful for the diagnosis of early-stage cancers. By contrast, reflecting the complete independencE of anti-survivin and anti-p53 antibodies, the combination of detecting these two antibodies resulted in the highest positivity rate (35.6%) in early-stage disease (stage 0-I). These results suggest that the combined measurement of anti-survivin and anti-p53 antibodies may be useful for the detection of early-stage colon cancer.

Keywords: autoantibody; colon cancer; colon polyp; inhibitor of apoptosis protein

References

  1. Int J Cancer. 2007 Jun 1;120(11):2344-52 - PubMed
  2. Lung Cancer. 2005 May;48(2):217-21 - PubMed
  3. Cancer Lett. 2009 Sep 18;282(2):159-66 - PubMed
  4. Gut. 1997 Mar;40(3):356-61 - PubMed
  5. Clin Chem. 2003 Jul;49(7):1206-8 - PubMed
  6. Clin Chem Lab Med. 2010 May;48(5):719-25 - PubMed
  7. Lung Cancer. 2004 Dec;46(3):299-304 - PubMed
  8. Oncogene. 2004 Jan 8;23(1):39-48 - PubMed
  9. Acta Otolaryngol. 2010 Aug;130(8):959-65 - PubMed
  10. Clin Cancer Res. 2005 Nov 1;11(21):7621-8 - PubMed
  11. Exp Cell Res. 2005 May 1;305(2):300-11 - PubMed
  12. Clin Chim Acta. 2005 Dec;362(1-2):125-30 - PubMed
  13. Ann Oncol. 2003 Jan;14(1):85-90 - PubMed
  14. Clin Cancer Res. 1995 Dec;1(12):1463-9 - PubMed
  15. J Immunol. 2004 Mar 15;172(6):3922-9 - PubMed
  16. Oncogene. 2005 Aug 4;24(33):5258-61 - PubMed
  17. Clin Chem. 2001 Sep;47(9):1729-31 - PubMed
  18. Cancer Res. 2000 Apr 1;60(7):1815-7 - PubMed
  19. BMC Cancer. 2009 Apr 27;9:125 - PubMed
  20. Clin Cancer Res. 2003 Nov 1;9(14):5120-6 - PubMed
  21. Autoimmunity. 2005 Sep;38(6):445-8 - PubMed
  22. Radiat Oncol. 2013 Dec 02;8:281 - PubMed

Publication Types